By: Dawit Astatike
Addis Ababa (Ethiopia Today), July 9, 2026: Ethiopia is finalizing the design phase for its first-ever state-of-the-art vaccine manufacturing factory, the Ethiopian Food and Drug Authority (EFDA) announced.
EFDA Director General Heran Gerba revealed that the construction of the facility will be managed under Ethiopian Investment Holdings (EIH).
The initiative aims to dramatically boost national vaccine supplies and guarantee medical independence, aligning with the African Union’s 2040 vision for the continent to self-produce 60% of its required vaccines.
To support this shift, the EFDA has rolled out advanced digitalization systems to monitor vaccine safety, quality, and human clinical trials. Furthermore, a specialized testing laboratory nearing completion in the Kality sub-city of Addis Ababa will soon grant Ethiopia full autonomy in vaccine testing and verification.
This regulatory push coincides with an unprecedented boom in local pharmaceutical manufacturing. Speaking at the 30th Regular Session of the House of Peoples’ Representatives, Prime Minister Dr. Abiy Ahmed announced that Ethiopia’s domestic medicine production capacity has skyrocketed from a mere 4% to an impressive 45%.
This massive growth is directly attributed to rigorous overhauls of the country’s drug quality control frameworks. Consequently, Ethiopia now ranks third in Africa for meeting international pharmaceutical regulatory agency standards, opening extensive opportunities to export locally produced medicines to global markets.
While the government invested over 60 billion Birr in medical equipment during the concluded 2018 Ethiopian fiscal year, most hardware is still imported.
Prime Minister Abiy stated that the strategic plan over the next five years is to construct advanced specialized facilities to aggressively scale up the domestic manufacturing of high-tech medical equipment alongside pharmaceuticals.